$RPTX
Repare Therapeutics Inc.

2021 Q4 Form 10-Q Financial Statement

#000095017021003910 Filed on November 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $6.877M $278.0K $0.00
YoY Change 4812.14%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.639M $6.596M $4.200M
YoY Change 118.26% 57.05% 223.08%
% of Gross Profit
Research & Development $27.97M $25.36M $10.09M
YoY Change 125.22% 151.32% 80.2%
% of Gross Profit
Depreciation & Amortization $368.0K $369.0K $210.0K
YoY Change 26.9% 75.71% 31.25%
% of Gross Profit
Operating Expenses $35.61M $31.96M $14.09M
YoY Change 123.83% 126.85% 104.16%
Operating Profit -$31.68M -$14.09M
YoY Change 124.88%
Interest Expense $52.00K $86.00K $450.0K
YoY Change -80.74% -80.89% -156.25%
% of Operating Profit
Other Income/Expense, Net -$20.00K $79.00K $442.0K
YoY Change 100.0% -82.13% -155.88%
Pretax Income -$28.70M -$31.60M -$13.65M
YoY Change 70.64% 131.59% 78.16%
Income Tax -$412.0K -$708.0K $106.0K
% Of Pretax Income
Net Earnings -$28.29M -$30.89M -$13.75M
YoY Change 85.39% 124.67% 78.57%
Net Earnings / Revenue -411.37% -11112.23%
Basic Earnings Per Share -$0.83
Diluted Earnings Per Share -$703.8K -$832.2K -$374.0K
COMMON SHARES
Basic Shares Outstanding 41.74M 37.12M
Diluted Shares Outstanding 37.12M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $334.4M $261.0M $347.9M
YoY Change 2.52% -24.98%
Cash & Equivalents $334.4M $261.0M $348.1M
Short-Term Investments $7.439M $7.200M
Other Short-Term Assets $6.314M $9.103M $8.500M
YoY Change -5.76% 7.09%
Inventory
Prepaid Expenses $6.314M $9.103M
Receivables
Other Receivables
Total Short-Term Assets $351.4M $280.4M $361.3M
YoY Change 1.4% -22.4%
LONG-TERM ASSETS
Property, Plant & Equipment $5.604M $4.165M $8.300M
YoY Change 41.95% -49.82%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $586.0K $1.008M $700.0K
YoY Change 103.47% 44.0%
Total Long-Term Assets $17.30M $15.27M $8.900M
YoY Change 64.24% 71.56%
TOTAL ASSETS
Total Short-Term Assets $351.4M $280.4M $361.3M
Total Long-Term Assets $17.30M $15.27M $8.900M
Total Assets $368.7M $295.6M $370.2M
YoY Change 3.26% -20.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.302M $1.860M $1.800M
YoY Change 2.27% 3.33%
Accrued Expenses $19.97M $12.08M $5.600M
YoY Change 207.17% 115.77%
Deferred Revenue $11.92M $8.925M $2.150M
YoY Change 475.06% 315.12%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $35.09M $23.41M $10.20M
YoY Change 218.59% 129.51%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $45.21M $53.98M $59.30M
YoY Change -23.64% -8.97%
Total Long-Term Liabilities $45.21M $53.98M $59.30M
YoY Change -23.64% -8.97%
TOTAL LIABILITIES
Total Short-Term Liabilities $35.09M $23.41M $10.20M
Total Long-Term Liabilities $45.21M $53.98M $59.30M
Total Liabilities $80.29M $77.39M $69.40M
YoY Change 14.29% 11.52%
SHAREHOLDERS EQUITY
Retained Earnings -$210.3M -$182.0M
YoY Change 103.43%
Common Stock $498.7M $400.2M
YoY Change 27.81%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $288.4M $218.3M $300.8M
YoY Change
Total Liabilities & Shareholders Equity $368.7M $295.6M $370.2M
YoY Change 3.26% -20.14%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$28.29M -$30.89M -$13.75M
YoY Change 85.39% 124.67% 78.57%
Depreciation, Depletion And Amortization $368.0K $369.0K $210.0K
YoY Change 26.9% 75.71% 31.25%
Cash From Operating Activities -$20.74M -$32.77M -$20.11M
YoY Change 60.26% 62.97% 243.76%
INVESTING ACTIVITIES
Capital Expenditures -$165.0K -$324.0K -$480.0K
YoY Change -90.41% -32.5% -366.67%
Acquisitions
YoY Change
Other Investing Activities -$233.0K -$65.00K
YoY Change -96.91%
Cash From Investing Activities -$398.0K -$389.0K -$480.0K
YoY Change -95.69% -18.96% 166.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 94.56M 363.0K -1.700M
YoY Change 32507.59% -121.35% -102.07%
NET CHANGE
Cash From Operating Activities -20.74M -32.77M -20.11M
Cash From Investing Activities -398.0K -389.0K -480.0K
Cash From Financing Activities 94.56M 363.0K -1.700M
Net Change In Cash 73.43M -32.80M -22.29M
YoY Change -435.43% 47.15% -129.25%
FREE CASH FLOW
Cash From Operating Activities -$20.74M -$32.77M -$20.11M
Capital Expenditures -$165.0K -$324.0K -$480.0K
Free Cash Flow -$20.57M -$32.45M -$19.63M
YoY Change 83.36% 65.3% 225.54%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
us-gaap Preferred Stock Shares Authorized Unlimited
PreferredStockSharesAuthorizedUnlimited
Unlimited
CY2020 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
dei Amendment Flag
AmendmentFlag
false
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2020 us-gaap Preferred Stock Shares Authorized Unlimited
PreferredStockSharesAuthorizedUnlimited
Unlimited
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001808158
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
A8
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39335
dei Entity Registrant Name
EntityRegistrantName
Repare Therapeutics Inc.
dei Entity Address Address Line1
EntityAddressAddressLine1
7210 Frederick-Banting
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
St-Laurent
dei Entity Address State Or Province
EntityAddressStateOrProvince
QC
dei Entity Address Country
EntityAddressCountry
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
H4S 2A1
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
412-7018
dei Security12b Title
Security12bTitle
Common shares, no par value
dei Trading Symbol
TradingSymbol
RPTX
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
41735057
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
260995000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
326184000
CY2021Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
7194000
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
7526000
CY2021Q3 rptx Research And Development Tax Credits Receivable
ResearchAndDevelopmentTaxCreditsReceivable
2317000
CY2020Q4 rptx Research And Development Tax Credits Receivable
ResearchAndDevelopmentTaxCreditsReceivable
2011000
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
CY2021Q3 us-gaap Other Receivables
OtherReceivables
767000
CY2020Q4 us-gaap Other Receivables
OtherReceivables
4153000
CY2021Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
9103000
CY2021Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
147000
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
6678000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
280376000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
346552000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4165000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3948000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
212000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7253000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4674000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1008000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
288000
CY2021Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
2843000
CY2020Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
1412000
CY2021Q3 us-gaap Assets
Assets
295645000
CY2020Q4 us-gaap Assets
Assets
357086000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1860000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2251000
CY2021Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
11020000
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
5975000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1458000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
697000
CY2021Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
8925000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2073000
CY2020Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
18000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
23410000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11014000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5623000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3308000
CY2021Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
48359000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
55934000
CY2021Q3 us-gaap Liabilities
Liabilities
77392000
CY2020Q4 us-gaap Liabilities
Liabilities
70256000
CY2021Q3 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2020Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2020Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37133938
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37133938
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36902924
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36902924
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
385990000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
384313000
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
14239000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
5875000
CY2021Q3 us-gaap Investment Income Net
InvestmentIncomeNet
53000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25361000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-181976000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-103358000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
218253000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
286830000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
295645000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
357086000
CY2021Q3 rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
278000
rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
723000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10091000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
62075000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27674000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6596000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3996000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18574000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9551000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
31957000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
14087000
us-gaap Operating Expenses
OperatingExpenses
80649000
us-gaap Operating Expenses
OperatingExpenses
37225000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-31679000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-14087000
us-gaap Operating Income Loss
OperatingIncomeLoss
-79926000
us-gaap Operating Income Loss
OperatingIncomeLoss
-37225000
CY2021Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
33000
CY2020Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
290000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-92000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-846000
CY2020Q3 us-gaap Investment Income Net
InvestmentIncomeNet
156000
us-gaap Investment Income Net
InvestmentIncomeNet
155000
us-gaap Investment Income Net
InvestmentIncomeNet
156000
CY2021Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
7000
CY2020Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
4000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
21000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
10000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
79000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
442000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
42000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-700000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-31600000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13645000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-79884000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-37925000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-708000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
106000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1266000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
300798000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
229000
CY2021Q3 rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-30892000
CY2020Q3 rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-13751000
rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-78618000
rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-38154000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-30892000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13751000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-78618000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-38154000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.83
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.12
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.63
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37122668
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36756694
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37026116
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14486896
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-46129000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
324000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
271000
CY2020Q1 rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-12601000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-58135000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
164000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
389000
CY2020Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
135997000
CY2020Q2 rptx Issuance Of Warrants And Conversion Into Common Stock During Period Value
IssuanceOfWarrantsAndConversionIntoCommonStockDuringPeriodValue
15000000
CY2020Q2 rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-11802000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
313656000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
22000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
871000
CY2020Q3 rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-13751000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
286830000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
183000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2057000
CY2021Q1 rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-21417000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
267653000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
449000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3183000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
113000
CY2021Q2 rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-26309000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
245089000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
80000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3693000
CY2021Q3 rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-30892000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
218253000
us-gaap Profit Loss
ProfitLoss
-78618000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-830000
us-gaap Profit Loss
ProfitLoss
-38154000
us-gaap Share Based Compensation
ShareBasedCompensation
8933000
us-gaap Share Based Compensation
ShareBasedCompensation
1531000
us-gaap Depreciation
Depreciation
1103000
us-gaap Depreciation
Depreciation
610000
us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
1248000
us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
520000
rptx Foreign Currency Transaction Gain Loss
ForeignCurrencyTransactionGainLoss
-10000
rptx Foreign Currency Transaction Gain Loss
ForeignCurrencyTransactionGainLoss
-835000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-85000
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
1431000
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
86000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
2425000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
8834000
rptx Increase Decrease In Research And Development Tax Credits Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable
295000
rptx Increase Decrease In Research And Development Tax Credits Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable
584000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-3429000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
1283000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
616000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-71000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-295000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1120000
rptx Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
5166000
rptx Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
3540000
rptx Increase Decrease In Operating Lease Liability Current
IncreaseDecreaseInOperatingLeaseLiabilityCurrent
-174000
rptx Increase Decrease In Operating Lease Liability Current
IncreaseDecreaseInOperatingLeaseLiabilityCurrent
-97000
us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
129000
us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
265000
rptx Increase Decrease In Operating Lease Liability Net
IncreaseDecreaseInOperatingLeaseLiabilityNet
-584000
rptx Increase Decrease In Operating Lease Liability Net
IncreaseDecreaseInOperatingLeaseLiabilityNet
-351000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-723000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
50000000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-65058000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
6863000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1525000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
516000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
5450000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
5203000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1278000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-516000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
712000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
510000
rptx Proceeds From Issuance Of Common Stock Under Two Thousand Twenty Employee Share Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan
283000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
15000000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
232043000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
995000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
247553000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-60000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-65401000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
253070000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
326396000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
95005000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
260995000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
348075000
CY2021Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
260995000
CY2020Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
347872000
CY2020Q3 us-gaap Restricted Cash
RestrictedCash
203000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
260995000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
348075000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
13000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
950000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3827000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4516000
rptx Deferred Financing Costs In Accruals And Other Current Liabilities
DeferredFinancingCostsInAccrualsAndOtherCurrentLiabilities
104000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
135997000
rptx Issuance Of Warrants And Conversion Into Common Stock During Period Value
IssuanceOfWarrantsAndConversionIntoCommonStockDuringPeriodValue
15000000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2016-09-06
CY2021Q3 rptx Fair Value Assets Transfers Between All Levels
FairValueAssetsTransfersBetweenAllLevels
0
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in consolidated financial statements and accompanying notes. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued research and development expenses, share-based compensation, right-of-use assets and lease liabilities and income taxes. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. The Company bases its estimates on historical experience and other market specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could materially differ from those estimates. Changes in estimates are recorded in the period in which they become known.</span></p>
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
9968000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
9968000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
9981000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
9981000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3361000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2771000
CY2021Q3 rptx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
6808000
CY2020Q4 rptx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
2584000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
456000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
436000
CY2021Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
395000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
184000
CY2021Q3 rptx Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
11020000
CY2020Q4 rptx Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
5975000
rptx Number Of Operating Leases
NumberOfOperatingLeases
5
us-gaap Lessee Operating Lease Existence Of Option To Terminate
LesseeOperatingLeaseExistenceOfOptionToTerminate
false
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
563000
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
249000
us-gaap Operating Lease Cost
OperatingLeaseCost
1406000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5256353
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.15
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4091510
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.28
us-gaap Operating Lease Cost
OperatingLeaseCost
579000
CY2021Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
22000
CY2020Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
34000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
27000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
38000
CY2021Q3 us-gaap Variable Lease Cost
VariableLeaseCost
20000
CY2020Q3 us-gaap Variable Lease Cost
VariableLeaseCost
16000
us-gaap Variable Lease Cost
VariableLeaseCost
130000
us-gaap Variable Lease Cost
VariableLeaseCost
108000
CY2021Q3 us-gaap Lease Cost
LeaseCost
605000
CY2020Q3 us-gaap Lease Cost
LeaseCost
299000
us-gaap Lease Cost
LeaseCost
1563000
us-gaap Lease Cost
LeaseCost
725000
us-gaap Operating Lease Payments
OperatingLeasePayments
913000
us-gaap Operating Lease Payments
OperatingLeasePayments
513000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3827000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4516000
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y6M3D
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y4M13D
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.040
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.052
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4132123
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.39
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3505119
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.07
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1426616
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
35.73
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
899274
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
16.61
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
217772
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.28
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
278246
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.83
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
84614
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
26.95
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
34637
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.96
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7199
CY2020Q3 rptx Net Income Loss Attributable To Common Stockholders Basic And Diluted
NetIncomeLossAttributableToCommonStockholdersBasicAndDiluted
-13751000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7130
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7561
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
217772
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.28
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
700000
rptx Additional Paid In Capital Share Based Payment Arrangement Exercised Options Credited To Common Shares
AdditionalPaidInCapitalShareBasedPaymentArrangementExercisedOptionsCreditedToCommonShares
400000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
21.99
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
14.42
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
23.29
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.43
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0098
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0043
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0073
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0043
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M6D
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y25D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M26D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y25D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7610
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
36500000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y2M12D
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-30892000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13751000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-78618000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-38154000
CY2021Q3 rptx Net Income Loss Attributable To Common Stockholders Basic And Diluted
NetIncomeLossAttributableToCommonStockholdersBasicAndDiluted
-30892000
rptx Net Income Loss Attributable To Common Stockholders Basic And Diluted
NetIncomeLossAttributableToCommonStockholdersBasicAndDiluted
-78618000
rptx Net Income Loss Attributable To Common Stockholders Basic And Diluted
NetIncomeLossAttributableToCommonStockholdersBasicAndDiluted
-38154000
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37122668
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36756694
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37026116
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14486896
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.83
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.12
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.63

Files In Submission

Name View Source Status
0000950170-21-003910-index-headers.html Edgar Link pending
0000950170-21-003910-index.html Edgar Link pending
0000950170-21-003910.txt Edgar Link pending
0000950170-21-003910-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rptx-20210930.htm Edgar Link pending
rptx-20210930.xsd Edgar Link pending
rptx-20210930_cal.xml Edgar Link unprocessable
rptx-20210930_def.xml Edgar Link unprocessable
rptx-20210930_htm.xml Edgar Link completed
rptx-20210930_lab.xml Edgar Link unprocessable
rptx-20210930_pre.xml Edgar Link unprocessable
rptx-ex10_1.htm Edgar Link pending
rptx-ex31_1.htm Edgar Link pending
rptx-ex31_2.htm Edgar Link pending
rptx-ex32_1.htm Edgar Link pending
rptx-ex32_2.htm Edgar Link pending
Show.js Edgar Link pending